Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 24

1.

Preclinical immunogenicity and safety of the cGMP-grade placental malaria vaccine PRIMVAC.

Chêne A, Gangnard S, Guadall A, Ginisty H, Leroy O, Havelange N, Viebig NK, Gamain B.

EBioMedicine. 2019 Apr;42:145-156. doi: 10.1016/j.ebiom.2019.03.010. Epub 2019 Mar 15.

2.

First field efficacy trial of the ChAd63 MVA ME-TRAP vectored malaria vaccine candidate in 5-17 months old infants and children.

Tiono AB, Nébié I, Anagnostou N, Coulibaly AS, Bowyer G, Lam E, Bougouma EC, Ouedraogo A, Yaro JBB, Barry A, Roberts R, Rampling T, Bliss C, Hodgson S, Lawrie A, Ouedraogo A, Imoukhuede EB, Ewer KJ, Viebig NK, Diarra A, Leroy O, Bejon P, Hill AVS, Sirima SB.

PLoS One. 2018 Dec 12;13(12):e0208328. doi: 10.1371/journal.pone.0208328. eCollection 2018.

3.

Down-selection of the VAR2CSA DBL1-2 expressed in E. coli as a lead antigen for placental malaria vaccine development.

Chêne A, Gangnard S, Dechavanne C, Dechavanne S, Srivastava A, Tétard M, Hundt S, Leroy O, Havelange N, Viebig NK, Gamain B.

NPJ Vaccines. 2018 Jul 17;3:28. doi: 10.1038/s41541-018-0064-6. eCollection 2018.

4.

Safety and Immunogenicity of Malaria Vectored Vaccines Given with Routine Expanded Program on Immunization Vaccines in Gambian Infants and Neonates: A Randomized Controlled Trial.

Mensah VA, Roetynck S, Kanteh EK, Bowyer G, Ndaw A, Oko F, Bliss CM, Jagne YJ, Cortese R, Nicosia A, Roberts R, D'Alessio F, Leroy O, Faye B, Kampmann B, Cisse B, Bojang K, Gerry S, Viebig NK, Lawrie AM, Clarke E, Imoukhuede EB, Ewer KJ, Hill AVS, Afolabi MO.

Front Immunol. 2017 Nov 20;8:1551. doi: 10.3389/fimmu.2017.01551. eCollection 2017.

5.

Human vaccination against RH5 induces neutralizing antimalarial antibodies that inhibit RH5 invasion complex interactions.

Payne RO, Silk SE, Elias SC, Miura K, Diouf A, Galaway F, de Graaf H, Brendish NJ, Poulton ID, Griffiths OJ, Edwards NJ, Jin J, Labbé GM, Alanine DG, Siani L, Di Marco S, Roberts R, Green N, Berrie E, Ishizuka AS, Nielsen CM, Bardelli M, Partey FD, Ofori MF, Barfod L, Wambua J, Murungi LM, Osier FH, Biswas S, McCarthy JS, Minassian AM, Ashfield R, Viebig NK, Nugent FL, Douglas AD, Vekemans J, Wright GJ, Faust SN, Hill AV, Long CA, Lawrie AM, Draper SJ.

JCI Insight. 2017 Nov 2;2(21). pii: 96381. doi: 10.1172/jci.insight.96381.

6.

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.

Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, Edwards NJ, Tarama C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Afolabi MO, Tiono AB, Yaro JB, Adetifa UJ, Hodgson SH, Anagnostou NA, Roberts R, Duncan CJ, Cortese R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampmann B, Imoukhuede EB, Sirima SB, Bojang K, Hill AV, Nébié I, Ewer KJ.

Mol Ther. 2017 Feb 1;25(2):547-559. doi: 10.1016/j.ymthe.2016.11.003.

7.

Safety, Immunogenicity and Efficacy of Prime-Boost Vaccination with ChAd63 and MVA Encoding ME-TRAP against Plasmodium falciparum Infection in Adults in Senegal.

Mensah VA, Gueye A, Ndiaye M, Edwards NJ, Wright D, Anagnostou NA, Syll M, Ndaw A, Abiola A, Bliss C, Gomis JF, Petersen I, Ogwang C, Dieye T, Viebig NK, Lawrie AM, Roberts R, Nicosia A, Faye B, Gaye O, Leroy O, Imoukhuede EB, Ewer KJ, Bejon P, Hill AV, Cisse B; MVVC group.

PLoS One. 2016 Dec 15;11(12):e0167951. doi: 10.1371/journal.pone.0167951. eCollection 2016.

8.

Clinical development of placental malaria vaccines and immunoassays harmonization: a workshop report.

Chêne A, Houard S, Nielsen MA, Hundt S, D'Alessio F, Sirima SB, Luty AJ, Duffy P, Leroy O, Gamain B, Viebig NK.

Malar J. 2016 Sep 17;15:476. doi: 10.1186/s12936-016-1527-8.

9.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.

Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima SB.

Mol Ther. 2016 Aug;24(8):1470-7. doi: 10.1038/mt.2016.83. Epub 2016 Apr 25.

10.

Workshop report: Malaria vaccine development in Europe--preparing for the future.

Viebig NK, D'Alessio F, Draper SJ, Sim BK, Mordmüller B, Bowyer PW, Luty AJ, Jungbluth S, Chitnis CE, Hill AV, Kremsner P, Craig AG, Kocken CH, Leroy O.

Vaccine. 2015 Nov 17;33(46):6137-44. doi: 10.1016/j.vaccine.2015.09.074. Epub 2015 Oct 1. Review.

PMID:
26431986
11.

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults.

Ogwang C, Kimani D, Edwards NJ, Roberts R, Mwacharo J, Bowyer G, Bliss C, Hodgson SH, Njuguna P, Viebig NK, Nicosia A, Gitau E, Douglas S, Illingworth J, Marsh K, Lawrie A, Imoukhuede EB, Ewer K, Urban BC, Hill AVS, Bejon P; MVVC group.

Sci Transl Med. 2015 May 6;7(286):286re5. doi: 10.1126/scitranslmed.aaa2373.

12.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ.

Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.

13.

Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.

Afolabi MO, Adetifa JU, Imoukhuede EB, Viebig NK, Kampmann B, Bojang K.

Am J Trop Med Hyg. 2014 May;90(5):908-14. doi: 10.4269/ajtmh.13-0615. Epub 2014 Mar 10. Review.

14.

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K.

PLoS One. 2013;8(3):e57726. doi: 10.1371/journal.pone.0057726. Epub 2013 Mar 19.

15.

Var2CSA DBL6-epsilon domain expressed in HEK293 induces limited cross-reactive and blocking antibodies to CSA binding parasites.

Fernandez P, Viebig NK, Dechavanne S, Lépolard C, Gysin J, Scherf A, Gamain B.

Malar J. 2008 Sep 4;7:170. doi: 10.1186/1475-2875-7-170.

16.

Disruption of var2csa gene impairs placental malaria associated adhesion phenotype.

Viebig NK, Levin E, Dechavanne S, Rogerson SJ, Gysin J, Smith JD, Scherf A, Gamain B.

PLoS One. 2007 Sep 19;2(9):e910.

17.

Dissection of the role of PfEMP1 and ICAM-1 in the sensing of Plasmodium-falciparum-infected erythrocytes by natural killer cells.

Baratin M, Roetynck S, Pouvelle B, Lemmers C, Viebig NK, Johansson S, Bierling P, Scherf A, Gysin J, Vivier E, Ugolini S.

PLoS One. 2007 Feb 21;2(2):e228.

18.

Pregnancy-associated malaria: parasite binding, natural immunity and vaccine development.

Gamain B, Smith JD, Viebig NK, Gysin J, Scherf A.

Int J Parasitol. 2007 Mar;37(3-4):273-83. Epub 2006 Dec 22. Review.

PMID:
17224156
19.

The human placental derived BeWo cell line: a useful model for selecting Plasmodium falciparum CSA-binding parasites.

Viebig NK, Nunes MC, Scherf A, Gamain B.

Exp Parasitol. 2006 Feb;112(2):121-5. Epub 2005 Nov 7.

PMID:
16274691
20.

Adherence of Plasmodium falciparum infected erythrocytes to CHO-745 cells and inhibition of binding by protein A in the presence of human serum.

Andrews KT, Adams Y, Viebig NK, Lanzer M, Schwartz-Albiez R.

Int J Parasitol. 2005 Sep;35(10):1127-34.

PMID:
16051246
21.

A single member of the Plasmodium falciparum var multigene family determines cytoadhesion to the placental receptor chondroitin sulphate A.

Viebig NK, Gamain B, Scheidig C, Lépolard C, Przyborski J, Lanzer M, Gysin J, Scherf A.

EMBO Rep. 2005 Aug;6(8):775-81.

22.

Direct activation of human endothelial cells by Plasmodium falciparum-infected erythrocytes.

Viebig NK, Wulbrand U, Förster R, Andrews KT, Lanzer M, Knolle PA.

Infect Immun. 2005 Jun;73(6):3271-7.

23.

Evaluation of the role of the endocytic receptor L-SIGN for cytoadhesion of Plasmodium falciparum-infected erythrocytes.

Viebig NK, Andrews KT, Kooyk Yv, Lanzer M, Knolle PA.

Parasitol Res. 2005 Jun;96(4):247-52. Epub 2005 May 4.

PMID:
15875214
24.

A human schwannoma cell line supports the in vitro adhesion of Plasmodium falciparum infected erythrocytes to chondroitin-4-sulfate.

Andrews KT, Viebig NK, Wissing F, Klatt N, Oster N, Wickert H, Knolle P, Lanzer M.

Parasitol Res. 2003 Feb;89(3):188-93. Epub 2002 Oct 8.

PMID:
12541060

Supplemental Content

Loading ...
Support Center